查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1726154

神经生物标记市场规模、份额、趋势分析报告：按应用、类型、最终用途、地区和细分市场预测，2025 年至 2030 年

Neurological Biomarkers Market Size, Share & Trends Analysis Report By Application (Alzheimer's, Parkinson's, Multiple Sclerosis, Autism), By Type, By End Use, By Region, And Segment Forecasts, 2025 - 2030
出版日期: | 出版商: Grand View Research | 英文 120 Pages | 商品交期: 2-10个工作天内

价格

神经生物标记市场的成长和趋势

根据 Grand View Research, Inc. 的新报告，全球神经生物标记市场预计到 2030 年将达到 187.5 亿美元，2025 年至 2030 年期间的复合年增长率为 12.9%。

增加对神经生物标记研究和开发的资金以促进开发新药预计将推动市场成长。美国国家神经疾病和中风研究所为进行临床检验、分析检验和生物标记发现相关研究的研究人员提供资助机会，包括合作研究协议和研发津贴。

生物标记在神经系统疾病治疗的发展中发挥重要作用。近年来，对神经系统疾病治疗方法研究和开发的投入显着增加。例如，2020年12月，非营利研究基金会Target ALS宣布将为专注于发现ALS新型生物标誌物的计划提供1,500万美元的研究资金，预计这将在预测期内加速市场成长。

Quanterix Simoa（单分子阵列）等技术先进的产品的出现，这是一种具有高信噪比的数位化ELISA 测试。这项技术有助于克服与神经系统疾病相关的生物标记相关的血脑障壁问题。预计此类技术进步将推动市场成长。例如，2021 年 1 月，雅培宣布推出首个针对创伤性脑损伤（包括脑震盪）的快速血液检测。此测试测量脑外伤后血液中发现的某些蛋白质，如果测试结果为阴性，则可用于排除进行电脑断层扫描的必要性。

对此类诊断产品的认知度低、成本高以及神经科短缺或缺失等因素（尤其是在新兴和欠发达国家）可能会影响此类基于生物标誌物的诊断解决方案的采用。根据世界神经病学联合会对世界卫生组织84个成员国中的63个成员国进行的调查，63个国家中的31个国家的神经科大多在大城市工作。每位神经科服务的人口约为 6,240 至 4,750,000。

神经生物标记市场报告重点

  • 2024年，蛋白质体学将占据最大的市场占有率，并预计在预测期内保持其主导地位。蛋白质体学方法对于准确诊断疾病的发生和进展至关重要，因为它们可以仔细检测转译后修饰和蛋白质特征。
  • 由于患病率上升和研发活动活性化，帕金森氏症领域占据了最大的市场占有率。
  • 根据最终用途，研究机构和其他部门主导了神经生物标记市场。合作开发神经系统疾病治疗方法的研究机构正在使用生物标记来评估抗药性。
  • 由于美国和加拿大市场参与企业实力雄厚，且政府对新型生物标记开发的资助不断增加，北美在市场中占据主导地位。
  • 由于日本和澳洲等已开发经济体广泛采用技术先进的诊断产品，并且中国和印度等新兴经济体越来越多地采用这些产品，预计亚太地区将在预测期内显着增长。

目录

第一章调查方法与范围

第二章执行摘要

第三章 神经生物标记市场变数、趋势与范围

  • 神经生物材料市场的系统性概述
    • 母市场展望
  • 渗透和成长前景图
  • 管道分析
    • 阿兹海默症
    • 帕金森氏症
    • 多发性硬化症
    • 泛自闭症障碍
  • 市场动态
    • 市场驱动因素分析
    • 市场限制因素分析
  • 神经生物标记：市场分析工具
    • 产业分析—波特五力分析
    • PESTLE分析

4. 神经生物标记市场：細項分析（按类型），2018-2030

  • 神经生物标记市场：类型变异分析

5. 神经生物标记市场：細項分析、按应用，2018-2030 年

  • 神经生物标记市场：应用变异分析

6. 神经生物标记市场：細項分析、依最终用途，2018-2030 年

  • 神经生物标记市场：最终用途变异分析

7. 神经生物标记市场：区域細項分析，2018-2030

  • 区域市场概况
  • 北美洲
  • 欧洲
  • 亚太地区
  • 拉丁美洲
  • 中东和非洲

8. 神经生物标记市场：竞争分析

  • 公司分类
  • 战略地图
    • 新产品发布
    • 伙伴关係
    • 获得
    • 合作
    • 资金筹措
  • 2022年公司市场占有率分析
  • 公司简介
    • Abbott
    • Johnson & Johnson Services, Inc.
    • Bio-Rad Laboratories, Inc.
    • Alseres Pharmaceuticals, Inc.
    • Banyan Biomarkers, Inc.
    • Rules-Based Medicine
    • Thermo Fisher Scientific, Inc.
    • Diagenic Asa
    • Merck & Co., Inc.
    • Quanterix
Product Code: GVR-3-68038-823-7

Neurological Biomarkers Market Growth & Trends:

The global neurological biomarkers market size is expected to reach USD 18.75 billion by 2030, expanding at a CAGR of 12.9% from 2025 to 2030, according to a new report by Grand View Research, Inc. Increased funding for R&D of neurological biomarkers to boost development of new drugs is expected to impel market growth. National Institute of Neurological Disorders and Stroke provides funding opportunities such as cooperative agreements & development grants for researchers conducting studies related to clinical validation, analytical validation, & biomarker discovery.

Biomarkers play a significant role in the development of drugs for the treatment of neurological diseases. In recent years, there has been a significant rise in investments in the R&D of treatments for neurological diseases. For instance, in December 2020, Target ALS-a nonprofit research foundation-announced research funding of USD 15 million for a project focused on the discovery of novel biomarkers for ALS, which is anticipated to accelerate market growth in the forecast period.

Availability of technologically advanced products such as Quanterix Simoa (single-molecule array), which is a digitized ELISA test with a high signal-to-noise ratio. This technology helps overcome blood-brain barrier issues associated with neurological disease-related biomarkers. Such technological advancements are expected to drive market growth. For instance, in January 2021, Abbott introduced the first rapid blood test for traumatic brain injury, including concussion. This test measures a particular protein that is found in the blood after a traumatic brain injury and can be used to rule out the need for CT scanning in case of negative test results.

Factors such as lack of awareness about such diagnostic products & their high cost and limited availability or absence of neurologists, especially in developing & underdeveloped countries, could affect the adoption of such biomarker-based diagnostic solutions. According to a World Federation of Neurology survey of 63/84 WHO member countries, the majority of neurologists in 31/63 countries worked in major cities. One neurologist was serving a population of about 6,240 to 4,750,000.

Neurological Biomarkers Market Report Highlights:

  • In 2024, proteomic type accounted for the largest market share and is anticipated to maintain their dominance over the forecast period as these are essential for accurate diagnosis of disease onset and progression due to the careful detection of posttranslational modifications and protein signatures
  • Parkinson's disease segment held the largest market share owing to rising incidence and increasing R&D activities.
  • Based on end use, the research organizations and others segment dominated the neurological biomarkers market. Research organizations collaborating for the development of therapeutics for treating neurological disorders utilize biomarkers for assessing the drug tolerance.
  • North America dominated the market owing to presence of market players with strong presence in the U.S. & Canada, and increasing government funding for the development of novel biomarkers
  • Asia-Pacific is anticipated to witness significant growth over the forecast period owing to high adoption of technologically advanced diagnostic products in developed countries such as Japan & Australia and increasing adoption of these products in developing economies such as China and India.

Table of Contents

Chapter 1 Methodology And Scope

  • 1.1 Market Segmentation And Scope
    • 1.1.1 Segment Definition
      • 1.1.1.1 Application Segment
      • 1.1.1.2 Type Segment
      • 1.1.1.3 End Use Segment
  • 1.2 Regional Scope
  • 1.3 Estimates And Forecast Timeline
  • 1.4 Objectives
    • 1.4.1 Objective - 1
    • 1.4.2 Objective - 2
    • 1.4.3 Objective - 3
  • 1.5 Research Methodology
  • 1.6 Information Procurement
    • 1.6.1 Purchased Database
    • 1.6.2 Gvr's Internal Database
    • 1.6.3 Secondary Sources
    • 1.6.4 Primary Research
  • 1.7 Information Or Data Analysis
    • 1.7.1 Data Analysis Models
  • 1.8 Market Formulation & Validation
  • 1.9 Model Details
    • 1.9.1 Commodity Flow Analysis
  • 1.10 List Of Secondary Sources
  • 1.11 List Of Abbreviations

Chapter 2 Executive Summary

  • 2.1 Market Outlook
  • 2.2 Application And Type Snapshot
  • 2.3 End Use Snapshot
  • 2.4 Competitive Landscape Snapshot

Chapter 3 Neurological Biomarkers Market Variables, Trends, And Scope

  • 3.1 Neurological Biomarkers Market Lineage Outlook
    • 3.1.1 Parent Market Outlook
  • 3.2 Penetration And Growth Prospect Mapping
  • 3.3 Pipeline Analysis
    • 3.3.1 Alzheimer's Disease
    • 3.3.2 Parkinson's Disease
    • 3.3.3 Multiple Sclerosis
    • 3.3.4 Autism Spectrum Disorder
  • 3.4 Market Dynamics
    • 3.4.1 Market Driver Analysis
      • 3.4.1.1 Increasing Prevalence Of Neurological Diseases
      • 3.4.1.2 Technological Advancements
      • 3.4.1.3 Increased Funding For R&D In Biomarkers
    • 3.4.2 Market Restraint Analysis
      • 3.4.2.1 Lack Of Consumer Awareness
      • 3.4.2.2 Reimbursement Policies
  • 3.5 Neurological Biomarkers: Market Analysis Tools
    • 3.5.1 Industry Analysis - Porter's
    • 3.5.2 Pestle Analysis

Chapter 4 Neurological Biomarkers Market: Segment Analysis, By Type, 2018 - 2030 (USD Million)

  • 4.1 Neurological Biomarkers Market: Type Movement Analysis
    • 4.1.1 Genomic
      • 4.1.1.1 Genomic Neurological Biomarkers Market, 2018 - 2030 (USD Million)
    • 4.1.2 Proteomic
      • 4.1.2.1 Proteomic Neurological Biomarkers Market, 2018 - 2030 (USD Million)
    • 4.1.3 Metabolomic
      • 4.1.3.1 Metabolomic Neurological Biomarkers Market, 2018 - 2030 (USD Million)
    • 4.1.5 Imaging
      • 4.1.5.1 Imaging Neurological Biomarkers Market, 2018 - 2030 (USD Million)
    • 4.1.6 Others
      • 4.1.6.1 Others Neurological Biomarkers Market, 2018 - 2030 (USD Million)

Chapter 5 Neurological Biomarkers Market: Segment Analysis, By Application, 2018 - 2030 (USD Million)

  • 5.1 Neurological Biomarkers Market: Application Movement Analysis
    • 5.1.1 Alzheimer's Disease
      • 5.1.1.1 Alzheimer's Disease Market, 2018 - 2030 (USD Million)
    • 5.1.2 Parkinson's Disease
      • 5.1.2.1 Parkinson's Disease Market, 2018 - 2030 (USD Million)
    • 5.1.3 Multiple Sclerosis
      • 5.1.3.1 Multiple Sclerosis Market, 2018 - 2030 (USD Million)
    • 5.1.4 Autism Spectrum Disorder
      • 5.1.4.1 Autism Spectrum Disorder Market, 2018 - 2030 (USD Million)
    • 5.1.5 Others
      • 5.1.5.1 Others Market, 2018 - 2030 (USD Million)

Chapter 6 Neurological Biomarkers Market: Segment Analysis, By End Use, 2018 - 2030 (USD Million)

  • 6.1 Neurological Biomarkers Market: End Use Movement Analysis
    • 6.1.1 Research Organizations
      • 6.1.1.1 Research Organizations Market, 2018 - 2030 (USD Million)
    • 6.1.2 Pharma & Biotech Companies
      • 6.1.2.1 Pharma & Biotech Companies Market, 2018 - 2030 (USD Million)
    • 6.1.3 Clinical Diagnostics
      • 6.1.3.1 Clinical Diagnostics Market, 2018 - 2030 (USD Million)

Chapter 7 Neurological Biomarkers Market: Segment Analysis, By Region, 2018 - 2030 (USD Million)

  • 7.1 Regional Market Snapshot
  • 7.2 North America
    • 7.2.1 North America Neurological Biomarkers Market Estimates And Forecast, 2018 - 2030 (USD Million)
    • 7.2.2 U.S.
      • 7.2.2.1 U.S. Neurological Biomarkers Market, 2018 - 2030 (USD Million)
      • 7.2.2.2 Key Country Dynamics
      • 7.2.2.3 Regulatory Framework
      • 7.2.2.4 Reimbursement Scenario
    • 7.2.3 Canada
      • 7.2.3.1 Canada Neurological Biomarkers Market, 2018 - 2030 (USD Million)
      • 7.2.3.2 Key Country Dynamics
      • 7.2.3.3 Regulatory Framework
      • 7.2.3.4 Reimbursement Scenario
    • 7.2.4 Mexico
      • 7.2.4.1 Mexico Neurological Biomarkers Market, 2018 - 2030 (USD Million)
      • 7.2.4.2 Key Country Dynamics
      • 7.2.4.3 Regulatory Framework
      • 7.2.4.4 Reimbursement Scenario
  • 7.3 Europe
    • 7.3.1 Europe Neurological Biomarkers Market, 2018 - 2030 (USD Million)
    • 7.3.2 Uk
      • 7.3.2.1 Uk Neurological Biomarkers Market, 2018 - 2030 (USD Million)
      • 7.3.2.2 Key Country Dynamics
      • 7.3.2.3 Regulatory Framework
      • 7.3.2.4 Reimbursement Scenario
    • 7.3.3 Germany
      • 7.3.3.1 Germany Neurological Biomarkers Market, 2018 - 2030 (USD Million)
      • 7.3.3.2 Key Country Dynamics
      • 7.3.3.3 Regulatory Framework
      • 7.3.3.4 Reimbursement Scenario
    • 7.3.4 Spain
      • 7.3.4.1 Spain Neurological Biomarkers Market, 2018 - 2030 (USD Million)
      • 7.3.4.2 Key Country Dynamics
      • 7.3.4.3 Regulatory Framework
      • 7.3.4.4 Reimbursement Scenario
    • 7.3.5 France
      • 7.3.5.1 France Neurological Biomarkers Market, 2018 - 2030 (USD Million)
      • 7.3.5.2 Key Country Dynamics
      • 7.3.5.3 Regulatory Framework
      • 7.3.5.4 Reimbursement Scenario
    • 7.3.6 Italy
      • 7.3.6.1 Italy Neurological Biomarkers Market, 2018 - 2030 (USD Million)
      • 7.3.6.2 Key Country Dynamics
      • 7.3.6.3 Regulatory Framework
      • 7.3.6.4 Reimbursement Scenario
    • 7.3.7 Denmark
      • 7.3.7.1 Denmark Neurological Biomarkers Market, 2018 - 2030 (USD Million)
      • 7.3.7.2 Key Country Dynamics
      • 7.3.7.3 Regulatory Framework
      • 7.3.7.4 Reimbursement Scenario
    • 7.3.8 Sweden
      • 7.3.8.1 Sweden Neurological Biomarkers Market, 2018 - 2030 (USD Million)
      • 7.3.8.2 Key Country Dynamics
      • 7.3.8.3 Regulatory Framework
      • 7.3.8.4 Reimbursement Scenario
    • 7.3.9 Norway
      • 7.3.9.1 Norway Neurological Biomarkers Market, 2018 - 2030 (USD Million)
      • 7.3.9.2 Key Country Dynamics
      • 7.3.9.3 Regulatory Framework
      • 7.3.9.4 Reimbursement Scenario
  • 7.4 Asia Pacific
    • 7.4.1 Asia-Pacific Neurological Biomarkers Market, 2018 - 2030 (USD Million)
    • 7.4.2 Japan
      • 7.4.2.1 Japan Neurological Biomarkers Market, 2018 - 2030 (USD Million)
      • 7.4.2.2 Key Country Dynamics
      • 7.4.2.3 Regulatory Framework
      • 7.4.2.4 Reimbursement Scenario
    • 7.4.3 China
      • 7.4.3.1 China Neurological Biomarkers Market, 2018 - 2030 (USD Million)
      • 7.4.3.2 Key Country Dynamics
      • 7.4.3.3 Regulatory Framework
      • 7.4.3.4 Reimbursement Scenario
    • 7.4.4 India
      • 7.4.4.1 India Neurological Biomarkers Market, 2018 - 2030 (USD Million)
      • 7.4.4.2 Key Country Dynamics
      • 7.4.4.3 Regulatory Framework
      • 7.4.4.4 Reimbursement Scenario
    • 7.4.5 South Korea
      • 7.4.5.1 South Korea Neurological Biomarkers Market, 2018 - 2030 (USD Million)
      • 7.4.5.2 Key Country Dynamics
      • 7.4.5.3 Regulatory Framework
      • 7.4.5.4 Reimbursement Scenario
    • 7.4.6 Thailand
      • 7.4.6.1 Thailand Neurological Biomarkers Market, 2018 - 2030 (USD Million)
      • 7.4.6.2 Key Country Dynamics
      • 7.4.6.3 Regulatory Framework
      • 7.4.6.4 Reimbursement Scenario
    • 7.4.7 Australia
      • 7.4.7.1 Australia Neurological Biomarkers Market, 2018 - 2030 (USD Million)
      • 7.4.7.2 Key Country Dynamics
      • 7.4.7.3 Regulatory Framework
      • 7.4.7.4 Reimbursement Scenario
  • 7.5 Latin America
    • 7.5.1 Latin America Neurological Biomarkers Market, 2018 - 2030 (USD Million)
    • 7.5.2 Brazil
      • 7.5.2.1 Brazil Neurological Biomarkers Market, 2018 - 2030 (USD Million)
      • 7.5.2.2 Key Country Dynamics
      • 7.5.2.3 Regulatory Framework
      • 7.5.2.4 Reimbursement Scenario
    • 7.5.3 Argentina
      • 7.5.3.1 Argentina Neurological Biomarkers Market, 2018 - 2030 (USD Million)
      • 7.5.3.2 Key Country Dynamics
      • 7.5.3.3 Regulatory Framework
      • 7.5.2.4 Reimbursement Scenario
  • 7.6 MEA
    • 7.6.1 MEA Neurological Biomarkers Market, 2018 - 2030 (USD Million)
    • 7.6.2 South Africa
      • 7.6.2.1 South Africa Neurological Biomarkers Market, 2018 - 2030 (USD Million)
      • 7.6.2.2 Key Country Dynamics
      • 7.6.2.3 Regulatory Framework
      • 7.6.2.4 Reimbursement Scenario
    • 7.6.3 Saudi Arabia
      • 7.6.3.1 Saudi Arabia Neurological Biomarkers Market, 2018 - 2030 (USD Million)
      • 7.6.3.2 Key Country Dynamics
      • 7.6.3.3 Regulatory Framework
      • 7.6.3.4 Reimbursement Scenario
    • 7.6.4 UAE
      • 7.6.4.1 UAE Neurological Biomarkers Market, 2018 - 2030 (USD Million)
      • 7.6.4.2 Key Country Dynamics
      • 7.6.4.3 Regulatory Framework
      • 7.6.2.4 Reimbursement Scenario
    • 7.6.5 Kuwait
      • 7.6.5.1 Kuwait Neurological Biomarkers Market, 2018 - 2030 (USD Million)
      • 7.6.5.2 Key Country Dynamics
      • 7.6.5.3 Regulatory Framework
      • 7.6.5.4 Reimbursement Scenario

Chapter 8 Neurological Biomarkers Market: Competitive Analysis

  • 8.1 Company Categorization
  • 8.2 Strategy Mapping
    • 8.2.1 New Product Launch
    • 8.2.2 Partnerships
    • 8.2.3 Acquisition
    • 8.2.4 Collaboration
    • 8.2.5 Funding
  • 8.3 Company Market Share Analysis, 2022
  • 8.4 Company Profiles
    • 8.4.1 Abbott
      • 8.4.1.1 Company Overview
      • 8.4.1.2 Financial Performance
      • 8.4.1.3 Product Benchmarking
      • 8.4.1.4 Strategic Initiatives
    • 8.4.2 Johnson & Johnson Services, Inc.
      • 8.4.2.1 Company Overview
      • 8.4.2.2 Financial Performance
      • 8.4.2.3 Product Benchmarking
      • 8.4.2.4 Strategic Initiatives
    • 8.4.3 Bio-Rad Laboratories, Inc.
      • 8.4.3.1 Company Overview
      • 8.4.3.2 Financial Performance
      • 8.4.3.3 Product Benchmarking
      • 8.4.3.4 Strategic Initiatives
    • 8.4.4 Alseres Pharmaceuticals, Inc.
      • 8.4.4.1 Company Overview
      • 8.4.4.2 Product Benchmarking
    • 8.4.5 Banyan Biomarkers, Inc.
      • 8.4.5.1 Company Overview
      • 8.4.5.2 Product Benchmarking
      • 8.4.5.3 Strategic Initiatives
    • 8.4.6 Rules-Based Medicine
      • 8.4.6.1 Company Overview
      • 8.4.6.2 Financial Performance
      • 8.4.6.3 Product Benchmarking
      • 8.4.6.4 Strategic Initiatives
    • 8.4.7 Thermo Fisher Scientific, Inc.
      • 8.4.7.1 Company Overview
      • 8.4.7.2 Financial Performance
      • 8.4.7.3 Product Benchmarking
      • 8.4.7.4 Strategic Initiatives
    • 8.4.8 Diagenic Asa
      • 8.4.8.1 Company Overview
      • 8.4.8.2 Product Benchmarking
    • 8.4.9 Merck & Co., Inc.
      • 8.4.9.1 Company Overview
      • 8.4.9.2 Financial Performance
      • 8.4.9.3 Product Benchmarking
      • 8.4.9.4 Strategic Initiatives
    • 8.4.10 Quanterix
      • 8.4.10.1 Company Overview
      • 8.4.10.2 Product Benchmarking
      • 8.4.10.3 Strategic Initiatives

List of Tables

  • Table 1 List of Abbreviation
  • Table 2 North America neurological biomarkers market, by application, 2018 - 2030 (USD Million)
  • Table 3 North America neurological biomarkers market, by type, 2018 - 2030 (USD Million)
  • Table 4 North America neurological biomarkers market, by end-use, 2018 - 2030 (USD Million)
  • Table 5 U.S. neurological biomarkers market, by application, 2018 - 2030 (USD Million)
  • Table 6 U.S. neurological biomarkers market, by type, 2018 - 2030 (USD Million)
  • Table 7 U.S. neurological biomarkers market, by end-use, 2018 - 2030 (USD Million)
  • Table 8 Canada neurological biomarkers market, by application, 2018 - 2030 (USD Million)
  • Table 9 Canada neurological biomarkers market, by type, 2018 - 2030 (USD Million)
  • Table 10 Canada neurological biomarkers market, by end-use, 2018 - 2030 (USD Million)
  • Table 11 Mexico neurological biomarkers market, by application, 2018 - 2030 (USD Million)
  • Table 12 Mexico neurological biomarkers market, by type, 2018 - 2030 (USD Million)
  • Table 13 Mexico neurological biomarkers market, by end-use, 2018 - 2030 (USD Million)
  • Table 14 Europe neurological biomarkers market, by application, 2018 - 2030 (USD Million)
  • Table 15 Europe neurological biomarkers market, by type, 2018 - 2030 (USD Million)
  • Table 16 Europe neurological biomarkers market, by end-use, 2018 - 2030 (USD Million)
  • Table 17 UK neurological biomarkers market, by application, 2018 - 2030 (USD Million)
  • Table 18 UK neurological biomarkers market, by type, 2018 - 2030 (USD Million)
  • Table 19 UK neurological biomarkers market, by end-use, 2018 - 2030 (USD Million)
  • Table 20 Germany neurological biomarkers market, by application, 2018 - 2030 (USD Million)
  • Table 21 Germany neurological biomarkers market, by type, 2018 - 2030 (USD Million)
  • Table 22 Germany neurological biomarkers market, by end-use, 2018 - 2030 (USD Million)
  • Table 23 France neurological biomarkers market, by application, 2018 - 2030 (USD Million)
  • Table 24 France neurological biomarkers market, by type, 2018 - 2030 (USD Million)
  • Table 25 France neurological biomarkers market, by end-use, 2018 - 2030 (USD Million)
  • Table 26 Italy neurological biomarkers market, by application, 2018 - 2030 (USD Million)
  • Table 27 Italy neurological biomarkers market, by type, 2018 - 2030 (USD Million)
  • Table 28 Italy neurological biomarkers market, by end-use, 2018 - 2030 (USD Million)
  • Table 29 Spain neurological biomarkers market, by application, 2018 - 2030 (USD Million)
  • Table 30 Spain neurological biomarkers market, by type, 2018 - 2030 (USD Million)
  • Table 31 Spain neurological biomarkers market, by end-use, 2018 - 2030 (USD Million)
  • Table 32 Denmark neurological biomarkers market, by application, 2018 - 2030 (USD Million)
  • Table 33 Denmark neurological biomarkers market, by type, 2018 - 2030 (USD Million)
  • Table 34 Denmark neurological biomarkers market, by end-use, 2018 - 2030 (USD Million)
  • Table 35 Sweden neurological biomarkers market, by application, 2018 - 2030 (USD Million)
  • Table 36 Sweden neurological biomarkers market, by type, 2018 - 2030 (USD Million)
  • Table 37 Sweden neurological biomarkers market, by end-use, 2018 - 2030 (USD Million)
  • Table 38 Norway neurological biomarkers market, by application, 2018 - 2030 (USD Million)
  • Table 39 Norway neurological biomarkers market, by type, 2018 - 2030 (USD Million)
  • Table 40 Norway neurological biomarkers market, by end-use, 2018 - 2030 (USD Million)
  • Table 41 Asia Pacific neurological biomarkers market, by application, 2018 - 2030 (USD Million)
  • Table 42 Asia Pacific neurological biomarkers market, by type, 2018 - 2030 (USD Million)
  • Table 43 Asia Pacific neurological biomarkers market, by end-use, 2018 - 2030 (USD Million)
  • Table 44 Japan neurological biomarkers market, by application, 2018 - 2030 (USD Million)
  • Table 45 Japan neurological biomarkers market, by type, 2018 - 2030 (USD Million)
  • Table 46 Japan neurological biomarkers market, by end-use, 2018 - 2030 (USD Million)
  • Table 47 China neurological biomarkers market, by application, 2018 - 2030 (USD Million)
  • Table 48 China neurological biomarkers market, by type, 2018 - 2030 (USD Million)
  • Table 49 China neurological biomarkers market, by end-use, 2018 - 2030 (USD Million)
  • Table 50 India neurological biomarkers market, by application, 2018 - 2030 (USD Million)
  • Table 51 India neurological biomarkers market, by type, 2018 - 2030 (USD Million)
  • Table 52 India neurological biomarkers market, by end-use, 2018 - 2030 (USD Million)
  • Table 53 South Korea neurological biomarkers market, by application, 2018 - 2030 (USD Million)
  • Table 54 South Korea neurological biomarkers market, by type, 2018 - 2030 (USD Million)
  • Table 55 South Korea neurological biomarkers market, by end-use, 2018 - 2030 (USD Million)
  • Table 56 Australia neurological biomarkers market, by application, 2018 - 2030 (USD Million)
  • Table 57 Australia neurological biomarkers market, by type, 2018 - 2030 (USD Million)
  • Table 58 Australia neurological biomarkers market, by end-use, 2018 - 2030 (USD Million)
  • Table 59 Thailand neurological biomarkers market, by application, 2018 - 2030 (USD Million)
  • Table 60 Thailand neurological biomarkers market, by type, 2018 - 2030 (USD Million)
  • Table 61 Thailand neurological biomarkers market, by end-use, 2018 - 2030 (USD Million)
  • Table 62 Latin America neurological biomarkers market, by application, 2018 - 2030 (USD Million)
  • Table 63 Latin America neurological biomarkers market, by type, 2018 - 2030 (USD Million)
  • Table 64 Latin America neurological biomarkers market, by end-use, 2018 - 2030 (USD Million)
  • Table 65 Brazil neurological biomarkers market, by application, 2018 - 2030 (USD Million)
  • Table 66 Brazil neurological biomarkers market, by type, 2018 - 2030 (USD Million)
  • Table 67 Brazil neurological biomarkers market, by end-use, 2018 - 2030 (USD Million)
  • Table 68 Argentina neurological biomarkers market, by application, 2018 - 2030 (USD Million)
  • Table 69 Argentina neurological biomarkers market, by type, 2018 - 2030 (USD Million)
  • Table 70 Argentina neurological biomarkers market, by end-use, 2018 - 2030 (USD Million)
  • Table 71 MEA neurological biomarkers market, by application, 2018 - 2030 (USD Million)
  • Table 72 MEA neurological biomarkers market, by type, 2018 - 2030 (USD Million)
  • Table 73 MEA neurological biomarkers market, by end-use, 2018 - 2030 (USD Million)
  • Table 74 South Africa neurological biomarkers market, by application, 2018 - 2030 (USD Million)
  • Table 75 South Africa neurological biomarkers market, by type, 2018 - 2030 (USD Million)
  • Table 76 South Africa neurological biomarkers market, by end-use, 2018 - 2030 (USD Million)
  • Table 77 Saudi Arabia neurological biomarkers market, by application, 2018 - 2030 (USD Million)
  • Table 78 Saudi Arabia neurological biomarkers market, by type, 2018 - 2030 (USD Million)
  • Table 79 Saudi Arabia neurological biomarkers market, by end-use, 2018 - 2030 (USD Million)
  • Table 80 UAE neurological biomarkers market, by application, 2018 - 2030 (USD Million)
  • Table 81 UAE neurological biomarkers market, by type, 2018 - 2030 (USD Million)
  • Table 82 UAE neurological biomarkers market, by end-use, 2018 - 2030 (USD Million)
  • Table 83 Kuwait neurological biomarkers market, by application, 2018 - 2030 (USD Million)
  • Table 84 Kuwait neurological biomarkers market, by type, 2018 - 2030 (USD Million)
  • Table 85 Kuwait neurological biomarkers market, by end-use, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Neurological biomarkers market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Information procurement
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Value-chain-based sizing & forecasting
  • Fig. 7 QFD modeling for market share assessment
  • Fig. 8 Market formulation & validation
  • Fig. 9 Market snapshot
  • Fig. 10 Segment snapshot (Type and application)
  • Fig. 11 Segment snapshot (End-use)
  • Fig. 12 Competitive landscape snapshot
  • Fig. 13 Biomarkers market value, 2022 (USD Million)
  • Fig. 14 Neurological biomarkers market dynamics
  • Fig. 15 Prevalence of Alzheimer's disease by age group, 2024
  • Fig. 16 Neurological biomarkers market: PORTER's analysis
  • Fig. 17 Neurological biomarkers market: PESTLE analysis
  • Fig. 18 Neurological biomarkers market: Type outlook and key takeaways
  • Fig. 19 Neurological biomarkers market: Type movement analysis
  • Fig. 20 Genomic neurological biomarkers market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 21 Proteomic neurological biomarkers market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 22 Metabolomic neurological biomarkers market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 23 Imaging market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 24 Other neurological biomarkers market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 25 Neurological biomarkers market: Application outlook and key takeaways
  • Fig. 26 Neurological biomarkers market: Application movement analysis
  • Fig. 27 Alzheimer's disease market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 28 Parkinson's disease market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 29 Multiple sclerosis market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 30 Autism spectrum disorder market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 31 Others market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 32 Neurological biomarkers market: End-use outlook and key takeaways
  • Fig. 33 Neurological biomarkers market: End-use movement analysis
  • Fig. 34 Research Organizations market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 35 Pharma & Biotech Companies market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 36 Clinical Diagnostics market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 37 Neurological biomarkers market revenue, by region, 2022 & 2030 (USD Million)
  • Fig. 38 Regional marketplace: Key takeaways
  • Fig. 39 Regional marketplace: Key takeaways
  • Fig. 40 North America market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 41 Key country dynamics
  • Fig. 42 U.S. neurological biomarkers market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 43 Target disease prevalence
  • Fig. 44 Key country dynamics
  • Fig. 45 Canada neurological biomarkers market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 46 Target disease prevalence
  • Fig. 47 Europe neurological biomarkers market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 48 Key country dynamics
  • Fig. 49 UK neurological biomarkers market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 50 Key country dynamics
  • Fig. 51 Germany neurological biomarkers market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 52 Target disease prevalence
  • Fig. 53 Key country dynamics
  • Fig. 54 France neurological biomarkers market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 55 Key country dynamics
  • Fig. 56 Italy neurological biomarkers market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 57 Key country dynamics
  • Fig. 58 Spain neurological biomarkers market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 59 Key country dynamics
  • Fig. 60 Denmark neurological biomarkers market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 61 Key country dynamics
  • Fig. 62 Sweden neurological biomarkers market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 63 Key country dynamics
  • Fig. 64 Norway neurological biomarkers market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 65 Target disease prevalence
  • Fig. 66 Rest of Europe market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 67 Asia Pacific market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 68 Key country dynamics
  • Fig. 69 Japan neurological biomarkers market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 70 Target disease prevalence
  • Fig. 71 Key country dynamics
  • Fig. 72 China neurological biomarkers market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 73 Key country dynamics
  • Fig. 74 India neurological biomarkers market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 75 Target disease prevalence
  • Fig. 76 Key country dynamics
  • Fig. 77 Australia neurological biomarkers market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 78 Key country dynamics
  • Fig. 79 Thailand neurological biomarkers market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 80 Key country dynamics
  • Fig. 81 South Korea neurological biomarkers market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 82 Rest of Asia Pacific market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 83 Latin America neurological biomarkers market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 84 Key country dynamics
  • Fig. 85 Brazil neurological biomarkers market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 86 Key country dynamics
  • Fig. 87 Mexico neurological biomarkers market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 88 Key country dynamics
  • Fig. 89 Argentina neurological biomarkers market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 90 Rest of Latin America neurological biomarkers market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 91 MEA neurological biomarkers market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 92 Key country dynamics
  • Fig. 93 South Africa neurological biomarkers market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 94 Target disease prevalence
  • Fig. 95 Key country dynamics
  • Fig. 96 Saudi Arabia neurological biomarkers market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 97 Target disease prevalence
  • Fig. 98 Key country dynamics
  • Fig. 99 UAE neurological biomarkers market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 100 Target disease prevalence
  • Fig. 101 Key country dynamics
  • Fig. 102 Kuwait neurological biomarkers market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 103 Target disease prevalence
  • Fig. 104 Key payors in Kuwait
  • Fig. 105 Rest of MEA neurological biomarkers market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 106 Key company categorization
  • Fig. 107 Company market positioning
  • Fig. 108 Company market share analysis, 2022
  • Fig. 109 Strategic framework